Safety and Efficacy Study of DuoTrav APS Versus DuoTrav

Alcon Research

Overview

The purpose of the study is to demonstrate that the IOP-lowering efficacy of DuoTrav APS, dosed once-daily in the morning, is non-inferior to that of DuoTrav, dosed once-daily in the morning.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Open-angle Glaucoma Ocular Hypertension

Interventions

DuoTrav APSDRUG

DuoTrav APS QD AM

DuoTravDRUG

DuoTrav QD AM

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with open-angle glaucoma or ocular hypertension who would benefit from a fixed combination medication, in the opinion of the investigator and who are currently on a stable treatment of IOP-lowering medication Exclusion Criteria: * VA not worse than 0.60 * additional clinically relevant ocular or systemic conditions may be excluded

Outcomes

Primary Outcomes

Mean Intraocular Pressure (IOP)

Time frame: 3 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.